<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869596</url>
  </required_header>
  <id_info>
    <org_study_id>0000-128</org_study_id>
    <secondary_id>2009_565</secondary_id>
    <nct_id>NCT00869596</nct_id>
  </id_info>
  <brief_title>Study of Biomarkers of Airway Inflammation (0000-128)</brief_title>
  <official_title>A Randomized Clinical Trial to Assess the Effects of Inhaled Fluticasone on Sputum Neutrophils After Low-dose Inhaled Endotoxin Challenge in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of inhaled fluticasone on cell counts and inflammatory
      mediators measured in sputum of healthy volunteers following exposure to inhaled
      lipopolysaccharide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum percent neutrophils</measure>
    <time_frame>6 hours following inhaled LPS challenge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum absolute neutrophils (per mL)</measure>
    <time_frame>6 hours following inhaled LPS challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum levels of IL1beta and IL8</measure>
    <time_frame>6 hours following inhaled LPS challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum mRNA expression levels of CD14 and IL1beta</measure>
    <time_frame>6 hours following inhaled LPS challenge</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Airway Inflammation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone 440 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone 1980 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
    <description>Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo to fluticasone</intervention_name>
    <description>Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Lipopolysaccharide (LPS)</intervention_name>
    <description>20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: albuterol</intervention_name>
    <description>Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects who can have children must have a negative pregnancy test at screening
             and agree to use two methods of birth control throughout the study

          -  Male subjects with female partner(s) who can have children agree to use an acceptable
             method of birth control throughout the study

          -  Subject is a nonsmoker

          -  Subject is in generally good health

          -  Subject is willing to comply with the diet, alcohol, and caffeine study restrictions

        Exclusion Criteria:

          -  Subject is a nursing mother

          -  Subject has taken oral corticosteroids within 8 weeks or inhaled/nasal corticosteroids
             within 4 weeks of screening

          -  Subject has nasal polyps, recent nasal surgery, or an ongoing upper or lower
             respiratory tract infection

          -  Subject has a recent history of allergic rhinitis at screening

          -  Subject has any respiratory disease at screening

          -  Subject has daily phlegm or a chronic cough

          -  Subject is unable to refrain from the use of any prescription or non-prescription
             drugs or herbal remedies during the study

          -  Subject consumes excessive amounts of alcohol or caffeine

          -  Subject has had major surgery, or donated or lost 1 unit of blood within 4 weeks of
             screening

          -  Subject has a history of stroke, seizures, or major neurological disorders

          -  Subject regularly uses illicit drugs or has a history of drug/alcohol abuse

          -  Subject received a vaccination within 3 weeks of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sputum inflammatory biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

